NEW YORK & NEWARK, Calif.–(BUSINESS WIRE)–The EyeQue Personal Vision Tracker earned the highest honor for CES 2017- Best of Innovation in the Fitness, Sports and Biotech category.
Category: News
Paintball Players Should Watch Out for Eye Injuries
Paintball and air guns account for one in 10 sports-related eye injuries and one-quarter of cases with vision impairment, a U.S. study suggests. Reuters Health Information
Glaukos Corporation Announces Third Quarter 2016 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Tobii Pro Launches Pioneering Eye Tracker and Biometric Software Platform for Behavioral Research
STOCKHOLM–(BUSINESS WIRE)–Tobii Pro (STO:TOBII), the global leader in eye tracking research solutions, continues to push the envelope in eye tracking innovation with the launch of Tobii Pro Spectrum and Tobii Pro Lab, its most advanced eye tracking solutions to date. These research tools – to be exhibited at Neuroscience 2016 (https://www.sfn.org/annual-meeting/neuroscience-2016) in San Diego, Calif. – from November 12-16 – will further expand the scope and richness of what can be achieved in
Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016
Pixium Vision’s Iris II Brings Back Sight to Blind for First Time
Pixium Vision, a company based in Paris, France, has announced that its Iris II bionic vision system has been implanted into the first patient. The Iris II was cleared in Europe back in July of this year and the UK regulatory authority, Medicines & Healthcare products Regulatory Agency (MHRA), gave a green light for a clinical trial [ (Read more...)
Keeping an Eye on Zika: Ocular Findings
Microcephaly is just one component of congenital Zika syndrome, and the ocular findings should not be overlooked, says a Brazilian ophthalmologist, who is now also practicing in the United States. Medscape Ophthalmology
Inotek Pharmaceuticals Corporation Reports Third Quarter 2016 Financial Results and Operational Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today reported financial results and operational highlights for the quarter ended September 30, 2016.
Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2016 and provided a general business update. “Following productive discussions with the FDA, we are preparing for the resubmission of our NDA for DEXTENZA™ for post-surgical ocular pain by the end of the year,
Trump Wins Presidency and Chance to Dump ACA
The real-estate magnate and reality-TV star who told raucous crowds that he would ‘Make America Great Again’ now will try to fulfil his promise to dismantle President Barack Obama’s signature legislation.
Medscape Medical News
Ophthotech Reports Third Quarter 2016 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company’s business and product development programs.
Ophthalmologists focus on dim-light driving situations that can endanger drivers and pedestrians
As the end of daylight saving time draws near, ophthalmologists at the Vanderbilt Eye Institute want to focus on a real issue — dim-light driving situations that can endanger drivers and pedestrians.
Dicerna Reports Third Quarter 2016 Financial and Operational Results
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals today reported financial and operational results for the third quarter ended September 30, 2016.
Hot Topics: Type 2 Diabetes
(MedPage Today) — What are the best courses of treatment for diabetic retinopathy?
Binocular Tx, Patching Boost Visual Acuity in Lazy Eye (CME/CE)
(MedPage Today) — But patching still offered superior results in kids age 5-12
Pixium Vision Announces the First Successful Implantation and Activation of IRIS® II, 150 Electrode Bionic Vision System, in the UK
PARIS & LONDON–(BUSINESS WIRE)–Regulatory News: Pixium Vision (Paris:PIX) (FR0011950641 – PIX, “Pixium”), a company developing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, announces the first successful implantation and activation of IRIS® II in the UK. This epi-retinal implant with 150 electrodes is intended for patients who have lost sight as a result of retinitis pigmentosa (RP). The first implant of IRIS® I
Pixium Vision annonce la réussite de l’implantation et l’activation du premier patient au Royaume-Uni avec son système de vision bionique IRIS®II doté de 150 électrodes
PARIS & LONDRES–(BUSINESS WIRE)–Regulatory News : Pixium Vision (Paris:PIX) (FR0011950641 – PIX), société qui développe des systèmes de vision bionique innovants en vue de permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce l’implantation et l’activation réussies du premier patient ayant perdu la vue suite à une rétinite pigmentaire, avec son système bionique IRIS® II, doté d’un implant épi-rétinien explantable de 150 électrodes, au Royaume-Uni. Cette première i
Genetic mutations that lead to macular degeneration blindness mapped by new research
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting infl…
Sports-related eye injuries higher among young people, study finds
Roughly 30,000 sports-related eye injuries serious enough to end in a visit to the emergency room occur each year in the United States, and the majority happen to those under the age of 18, new Johns Hopkins Bloomberg School of Public Health-led resear…